Register for email alerts and news feeds:
This journal | BMJ Group
rss
Published Online First: 7 September 2007. doi:10.1136/jcp.2007.047043
Journal of Clinical Pathology 2008;61:203-208
Copyright © 2008 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

ORIGINAL ARTICLES

Molecular alterations of KIT and PDGFRA in GISTs: evaluation of a Portuguese series

A L Gomes1, A Gouveia2,3,5, A F Capelinha2,4,5, D de la Cruz4, P Silva2,4,5, R M Reis1, A Pimenta3,4,5 and J M Lopes2,4,5

1 Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal
2 IPATIMUP, Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal
3 Department of Surgery, Porto University, Porto, Portugal
4 Department of Pathology, H.S. João, Porto University, Porto, Portugal
5 Medical Faculty of Porto University, Porto, Portugal

Correspondence to:
ProfessorDr José Manuel Lopes, Rua Roberto Frias, s/n, 4200-465 Porto, Portugal; jmlopes{at}ipatimup.pt

Aim: To assess KIT and PDGFRA mutations frequencies in a Portuguese series of gastrointestinal stromal tumours (GISTs).

Methods: 78 GISTs were evaluated for CD117 expression and screened for mutations in KIT (exons 9, 11, 13, 14 and 17) and PDGFRA (exons 12, 14 and 18) genes.

Results: KIT activating mutations were identified in 44 (56%) of the 78 GISTs. Forty cases (91%) presented a mutation in KIT exon 11, and 4 (9%) in exon 9. One case showed a 4 bp deletion in intron 14. PDGFRA mutations were observed in 5 cases (6%): 2 (3%) in exon 12 and 3 (4%) in exon 18. Survival analysis was performed in 63 of the 78 GISTs. The presence of mutated KIT was significantly correlated with shorter survival of patients (p = 0.0460), and inversely associated with epithelioid histological type of GISTs (p = 0.0064).

Conclusions: Overall, the incidence of both KIT and PDGFRA mutations in these Portuguese series was 63%, being in agreement with other studies, mainly of Iberian populations. The great majority of mutations were located in KIT exon 11, statistically associated with worse prognosis and indicative of favourable response to imatinib-based therapy in this Portuguese series of GISTs.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Pathology jobs

Pathology jobs